Please use this identifier to cite or link to this item: https://ir.swu.ac.th/jspui/handle/123456789/27151
Full metadata record
DC FieldValueLanguage
dc.contributor.authorRattanavipanon W.
dc.contributor.authorChaiyasothi T.
dc.contributor.authorPuchsaka P.
dc.contributor.authorMungkornkaew R.
dc.contributor.authorNathisuwan S.
dc.contributor.authorVeettil S.K.
dc.contributor.authorChaiyakunapruk N.
dc.date.accessioned2022-12-14T03:16:56Z-
dc.date.available2022-12-14T03:16:56Z-
dc.date.issued2022
dc.identifier.issn3065251
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85125997780&doi=10.1111%2fbcp.15279&partnerID=40&md5=f16c6cf1d00aae9f3285417e468a5641
dc.identifier.urihttps://ir.swu.ac.th/jspui/handle/123456789/27151-
dc.description.abstractAims: To grade the evidence from published meta-analyses of randomized controlled trials (RCTs) that assessed effects of pharmacist intervention on cardiovascular risk factors and cardiovascular outcomes. Methods: MEDLINE, Embase, and the Cochrane Library were searched from database inception to July 2021. Meta-analyses of RCTs were eligible. Quality of evidence were assessed by GRADE approach. Results: From 9308 publications, 149 full-text articles were evaluated for eligibility, and 24 studies with 85 unique meta-analyses that assessed effects of pharmacist intervention on cardiovascular risk factors and cardiovascular outcomes were selected. Overall, 71.7% (61/85) of unique meta-analyses showed significant impacts of pharmacist intervention. For the quality of evidence, 63.4% of meta-analyses had large heterogeneity (I2 > 50%) while 1.2, 16.5, 32.9 and 49.4% of meta-analyses were graded as high, moderate, low and very low quality based on GRADE approach, respectively. Among meta-analyses with moderate quality, pharmacist interventions significantly mitigated risk factors (including 6/3 mmHg reduction of blood pressure, increased the rate of lipid control, glucose control and smoking cessation (pooled odds ratio, [95% confidence interval] 1.91 [1.55, 2.35], 3.11 [2.3, 4.3] and 2.3 [1.33, 3.97], respectively) and improved medication adherence (1.67 [1.38, 2.02]). Furthermore, pharmacist interventions significantly reduced all-cause mortality (0.72 [0.58, 0.89]) and improved quality of life in patients suffering from chronic heart failure. Conclusion: This umbrella review found convincing evidence that pharmacist intervention can provide a wide range of benefits in cardiovascular disease management, ranging from risk factor control, improvement in medication adherence and, in some settings, reduction in morbidity and mortality. © 2022 British Pharmacological Society.
dc.languageen
dc.publisherJohn Wiley and Sons Inc
dc.subjectcardiovascular disease
dc.subjectintervention
dc.subjectmeta-analysis
dc.subjectpharmacist
dc.subjectumbrella review
dc.titleEffects of pharmacist interventions on cardiovascular risk factors and outcomes: An umbrella review of meta-analysis of randomized controlled trials
dc.typeOther
dc.rights.holderScopus
dc.identifier.bibliograpycitationClinical Ophthalmology. Vol 16, No. (2022), p.1871-1882
dc.identifier.doi10.1111/bcp.15279
Appears in Collections:Scopus 2022

Files in This Item:
There are no files associated with this item.


Items in SWU repository are protected by copyright, with all rights reserved, unless otherwise indicated.